{"hands_on_practices": [{"introduction": "The diagnosis of Eosinophilic Esophagitis (EoE) begins with endoscopy, where visual features can suggest the condition. To move beyond subjective descriptions, standardized tools like the Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) are vital for objectively grading disease severity and monitoring response to therapy. This exercise will sharpen your ability to translate qualitative endoscopic findings into a quantitative, clinically meaningful score, a core skill in modern gastroenterology practice [@problem_id:4832504].", "problem": "A patient with suspected Eosinophilic Esophagitis (EoE) undergoes esophagogastroduodenoscopy. The endoscopy report documents: decreased clarity of mucosal vascular markings throughout the esophagus, exactly two distinct fixed circumferential rings, scattered punctate white exudates without confluent plaques, and longitudinal furrows. No focal narrowing or small-caliber esophagus is noted, and there is no report of resistance to passage of a standard adult diagnostic upper endoscope.\n\nUse the Eosinophilic Esophagitis Endoscopic Reference Score (EREFS), a standardized classification that grades the following features based on endoscopic appearance:\n- Edema: score $0$ if absent (normal distinct vascularity), score $1$ if present (decreased or absent vascular markings).\n- Rings: score $0$ if none, score $1$ if mild (subtle, non-fixed circumferential ridges), score $2$ if moderate (distinct fixed rings), score $3$ if severe (small-caliber esophagus).\n- Exudates: score $0$ if none, score $1$ if mild (discrete specks involving less than $0.10$ of the esophageal mucosal surface area), score $2$ if severe (plaques involving at least $0.10$ of the esophageal mucosal surface area).\n- Furrows: score $0$ if absent, score $1$ if present.\n- Stricture: score $0$ if absent, score $1$ if present.\n\nStarting from these definitions and the pathophysiological correlation that mucosal edema in EoE manifests endoscopically as decreased vascular visibility, translate each reported finding into its EREFS component grade and compute the total EREFS by summing the component scores. Express your final result as an exact integer without units.", "solution": "The problem is first assessed for validity.\n\n**Step 1: Extract Givens**\nThe provided data from the problem statement are:\n- Endoscopic findings in a patient with suspected Eosinophilic Esophagitis (EoE):\n    - \"decreased clarity of mucosal vascular markings throughout the esophagus\"\n    - \"exactly two distinct fixed circumferential rings\"\n    - \"scattered punctate white exudates without confluent plaques\"\n    - \"longitudinal furrows\"\n    - \"No focal narrowing or small-caliber esophagus is noted\"\n    - \"no report of resistance to passage of a standard adult diagnostic upper endoscope\"\n- The Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) system definitions:\n    - Edema ($S_{edema}$): $0$ = absent (normal distinct vascularity); $1$ = present (decreased or absent vascular markings).\n    - Rings ($S_{rings}$): $0$ = none; $1$ = mild (subtle, non-fixed ridges); $2$ = moderate (distinct fixed rings); $3$ = severe (small-caliber esophagus).\n    - Exudates ($S_{exudates}$): $0$ = none; $1$ = mild (discrete specks, $ 0.10$ surface area); $2$ = severe (plaques, $\\ge 0.10$ surface area).\n    - Furrows ($S_{furrows}$): $0$ = absent; $1$ = present.\n    - Stricture ($S_{stricture}$): $0$ = absent; $1$ = present.\n- The task is to compute the total EREFS, which is the sum of the individual component scores.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientific Grounding:** The problem is scientifically grounded. Eosinophilic Esophagitis is a recognized medical condition, and the EREFS is a validated, widely used scoring system in gastroenterology for standardizing the endoscopic evaluation of EoE. The described findings and their correlation with the scoring components are factually correct and based on established clinical principles.\n- **Well-Posedness:** The problem is well-posed. It provides a complete set of clinical observations and a well-defined, discrete scoring rubric. The instructions to map the findings to the scores and sum them lead to a unique and meaningful integer result.\n- **Objectivity:** The problem is objective. The provided endoscopic descriptions and the EREFS definitions are clear and precise, allowing for a deterministic mapping without subjective interpretation.\n- **Consistency:** The given information is internally consistent. For example, the finding of \"no focal narrowing or small-caliber esophagus\" is consistent with the absence of a stricture and the absence of the most severe form of rings.\n\n**Step 3: Verdict and Action**\nThe problem is deemed valid as it is scientifically sound, well-posed, objective, and internally consistent. A solution will be formulated.\n\n**Solution Formulation**\nThe total Eosinophilic Esophagitis Endoscopic Reference Score ($S_{total}$) is calculated by summing the scores of its five components: Edema ($S_{edema}$), Rings ($S_{rings}$), Exudates ($S_{exudates}$), Furrows ($S_{furrows}$), and Stricture ($S_{stricture}$). Each component is scored by translating the endoscopic report's findings into the provided EREFS definitions.\n\n1.  **Edema Score ($S_{edema}$):**\n    The report states there is \"decreased clarity of mucosal vascular markings throughout the esophagus\". According to the EREFS definition, edema is scored as $1$ if present, which is indicated by \"decreased or absent vascular markings\".\n    Therefore, $S_{edema} = 1$.\n\n2.  **Rings Score ($S_{rings}$):**\n    The report documents \"exactly two distinct fixed circumferential rings\". The EREFS definition for a score of $2$ is \"moderate (distinct fixed rings)\". The absence of a \"small-caliber esophagus\" confirms the score is not $3$.\n    Therefore, $S_{rings} = 2$.\n\n3.  **Exudates Score ($S_{exudates}$):**\n    The finding is \"scattered punctate white exudates without confluent plaques\". This description aligns with the EREFS definition for a score of $1$, which is \"mild (discrete specks involving less than $0.10$ of the esophageal mucosal surface area)\". The term \"punctate\" corresponds to \"discrete specks\", and the absence of \"confluent plaques\" rules out a score of $2$.\n    Therefore, $S_{exudates} = 1$.\n\n4.  **Furrows Score ($S_{furrows}$):**\n    The report explicitly notes the presence of \"longitudinal furrows\". The EREFS definition for a score of $1$ is \"present\".\n    Therefore, $S_{furrows} = 1$.\n\n5.  **Stricture Score ($S_{stricture}$):**\n    The report states, \"No focal narrowing or small-caliber esophagus is noted, and there is no report of resistance to passage of a standard adult diagnostic upper endoscope.\" These observations confirm the absence of a stricture. The EREFS definition for a score of $0$ is \"absent\".\n    Therefore, $S_{stricture} = 0$.\n\n**Total EREFS Calculation:**\nThe total score is the sum of the individual component scores:\n$$S_{total} = S_{edema} + S_{rings} + S_{exudates} + S_{furrows} + S_{stricture}$$\nSubstituting the determined values:\n$$S_{total} = 1 + 2 + 1 + 1 + 0$$\n$$S_{total} = 5$$\nThe total Eosinophilic Esophagitis Endoscopic Reference Score is $5$.", "answer": "$$\n\\boxed{5}\n$$", "id": "4832504"}, {"introduction": "While endoscopy raises suspicion, the definitive diagnosis of EoE is made at the microscopic level, based on a peak eosinophil count of at least $15$ per high-power field (HPF). This practice moves from clinical scoring to the fundamental basis of histopathologic diagnosis, challenging you to calculate the expected eosinophil count from first principles. By relating cellular density derived from digital pathology to the physical area of a microscope's field of view, you will gain a deeper, quantitative appreciation for this critical diagnostic criterion [@problem_id:4832555].", "problem": "A 28-year-old patient with dysphagia undergoes esophageal mucosal biopsy for suspected eosinophilic esophagitis. Histopathologic diagnosis of eosinophilic esophagitis commonly relies on the peak eosinophil count per high-power field (HPF), measured on a light microscope at high magnification. The microscope’s field of view at the specimen plane is circular, and its measured diameter is $d = 0.55\\,\\mathrm{mm}$. A validated digital morphometry pipeline applied to the same section reports an areal eosinophil density of $\\rho = 6.3131 \\times 10^{1}\\,\\mathrm{mm}^{-2}$ within the squamous epithelium.\n\nFrom first principles—namely, that areal density equals number per unit area and that a circular field has area proportional to the square of its radius—derive an expression for the expected eosinophil count per HPF and use it to compute the numerical value for this specimen. Assume eosinophils are uniformly distributed within the field of view at this sampling scale. Round your answer to four significant figures and express it as a pure count (no units).", "solution": "The problem requires the derivation of an expression for the expected eosinophil count per high-power field (HPF), denoted as $N_{HPF}$, and the computation of its numerical value based on the provided data. The derivation must proceed from first principles.\n\nThe first principles provided in the problem statement are:\n1.  Areal density, $\\rho$, is defined as the number of entities, $N$, per unit area, $A$. This can be written mathematically as:\n    $$ \\rho = \\frac{N}{A} $$\n    From this, the number of entities within a given area can be calculated as:\n    $$ N = \\rho \\times A $$\n\n2.  The area of a circular field is proportional to the square of its radius, $r$. The exact formula for the area of a circle is:\n    $$ A = \\pi r^2 $$\n\nThe problem specifies that the high-power field (HPF) is a circular area. Let its area be $A_{HPF}$. The diameter of this field is given as $d$. The radius $r$ is related to the diameter by $r = \\frac{d}{2}$. Substituting this into the area formula gives the area of the HPF in terms of its diameter:\n$$ A_{HPF} = \\pi \\left(\\frac{d}{2}\\right)^2 = \\frac{\\pi d^2}{4} $$\n\nThe expected number of eosinophils within this field, $N_{HPF}$, can be found by applying the first principle. We are given the areal eosinophil density, $\\rho$, and we have just derived the area of the field, $A_{HPF}$. The problem states to assume a uniform distribution of eosinophils, which validates the use of the average density $\\rho$ over the entire area $A_{HPF}$.\n\nTherefore, the expression for the expected eosinophil count per HPF is:\n$$ N_{HPF} = \\rho \\times A_{HPF} $$\nSubstituting the expression for $A_{HPF}$:\n$$ N_{HPF} = \\rho \\left(\\frac{\\pi d^2}{4}\\right) = \\frac{\\pi \\rho d^2}{4} $$\nThis is the derived expression for the expected eosinophil count per HPF from the stated first principles.\n\nNow, we compute the numerical value for this specimen using the given data:\n-   Areal eosinophil density: $\\rho = 6.3131 \\times 10^{1}\\,\\mathrm{mm}^{-2}$\n-   Diameter of the HPF: $d = 0.55\\,\\mathrm{mm}$\n\nSubstituting these values into the derived expression:\n$$ N_{HPF} = \\frac{\\pi (6.3131 \\times 10^{1}\\,\\mathrm{mm}^{-2}) (0.55\\,\\mathrm{mm})^2}{4} $$\n\nFirst, calculate the square of the diameter:\n$$ d^2 = (0.55\\,\\mathrm{mm})^2 = 0.3025\\,\\mathrm{mm}^2 $$\n\nNow, substitute this back into the equation for $N_{HPF}$:\n$$ N_{HPF} = \\frac{\\pi (63.131\\,\\mathrm{mm}^{-2}) (0.3025\\,\\mathrm{mm}^2)}{4} $$\nThe units $(\\mathrm{mm}^{-2}) \\times (\\mathrm{mm}^2)$ cancel out, resulting in a dimensionless quantity (a pure count), as expected.\n\n$$ N_{HPF} = \\frac{\\pi \\times 63.131 \\times 0.3025}{4} $$\nEvaluating the numerator:\n$$ \\pi \\times 63.131 \\times 0.3025 \\approx (3.14159265...) \\times (19.0971775) \\approx 60.0009625... $$\nFinally, dividing by $4$:\n$$ N_{HPF} = \\frac{60.0009625...}{4} \\approx 15.0002406... $$\n\nThe problem requires the answer to be rounded to four significant figures. The first four significant figures are $1$, $5$, $0$, and $0$. The fifth significant figure is $0$, so we round down.\nThe computed value rounded to four significant figures is $15.00$.", "answer": "$$\\boxed{15.00}$$", "id": "4832555"}, {"introduction": "Once EoE is diagnosed, the clinician faces a complex decision regarding the optimal therapeutic strategy, balancing efficacy, cost, and potential adverse events in a multi-step treatment algorithm. This advanced problem immerses you in the practical application of decision analysis, a powerful method for navigating clinical uncertainty and resource allocation. By building and analyzing a two-stage decision tree, you will practice the high-level skill of selecting a management strategy that minimizes expected costs while satisfying a required probability of achieving histologic remission [@problem_id:4832507].", "problem": "A clinician is managing a patient with eosinophilic esophagitis (EoE) and must select an initial therapy among three evidence-based options, with a plan to escalate to a biologic therapy only if histologic remission is not achieved after the initial course. The goal is to minimize the expected total cost while ensuring that the overall probability of histologic remission meets a predefined threshold. Use the axioms of probability and the definition of expected value to construct and analyze a two-stage decision tree.\n\nDefine the two-stage strategy as follows: choose one initial therapy, reassess histology with endoscopy after $8$ weeks, and if remission has not been achieved, proceed to a single $12$-week course of a biologic, followed by repeat endoscopy. Assume independence between histologic remission and adverse events within and across therapies, and that adverse event costs are incurred only if the corresponding therapy is administered.\n\nInitial therapy options:\n- Proton pump inhibitor (PPI): direct $8$-week therapy cost $=$ $\\$200$, histologic remission probability $=$ $0.42$, adverse event probability $=$ $0.01$, adverse event management cost $=$ $\\$300$.\n- Swallowed topical corticosteroid (STC; budesonide): direct $8$-week therapy cost $=$ $\\$650$, histologic remission probability $=$ $0.65$, adverse event probability $=$ $0.03$, adverse event management cost $=$ $\\$150$.\n- Six-food elimination diet (SFED): direct $8$-week therapy cost $=$ $\\$400$, histologic remission probability $=$ $0.54$, adverse event probability $=$ $0$, adverse event management cost $=$ $\\$0$.\n\nRescue biologic therapy:\n- Dupilumab: direct $12$-week therapy cost $=$ $\\$9{,}600$, histologic remission probability $=$ $0.75$, adverse event probability $=$ $0.02$, adverse event management cost $=$ $\\$500$.\n\nEndoscopy:\n- Each histologic assessment endoscopy costs $\\$1{,}200$ and is performed after the initial $8$-week course and, if rescue therapy is used, after the $12$-week course.\n\nLet the predefined minimum acceptable overall probability of histologic remission be $R_{\\min} = 0.85$. The overall remission probability of a two-stage strategy equals the probability of remission after the initial therapy plus the probability of no remission after the initial therapy multiplied by the probability of remission after the rescue therapy.\n\nFor each choice of initial therapy, derive the expected total cost of the two-stage strategy and determine whether the overall remission probability constraint $R \\geq R_{\\min}$ is satisfied. Among the initial therapy options that satisfy the constraint, identify the strategy with the minimal expected total cost.\n\nExpress the minimal expected total cost in United States dollars (USD) and round your answer to four significant figures.", "solution": "The objective is to find the initial therapy strategy that minimizes the expected total cost while ensuring the overall probability of histologic remission is at least $R_{\\min} = 0.85$.\n\nFirst, we define the general formulas for any initial therapy $i$. Let:\n- $p_i$ be the remission probability for initial therapy $i$.\n- $C_i$ be the direct cost of initial therapy $i$.\n- $q_i$ be the adverse event (AE) probability for initial therapy $i$.\n- $C_{AE,i}$ be the management cost for an AE from therapy $i$.\n- $p_D = 0.75$ be the remission probability for the rescue biologic (Dupilumab).\n- $C_D = \\$9,600$ be the cost of the rescue biologic.\n- $q_D = 0.02$ be the AE probability for the rescue biologic.\n- $C_{AE,D} = \\$500$ be the AE management cost for the rescue biologic.\n- $C_{endo} = \\$1,200$ be the cost of one endoscopy.\n\n**Overall Remission Probability ($R_{overall,i}$):**\nThe overall probability of remission is the probability of remission after the first stage plus the probability of failing the first stage and achieving remission in the second stage.\n$$R_{overall,i} = p_i + (1 - p_i) \\times p_D$$\n\n**Expected Total Cost ($E[C_i]$):**\nThe expected cost is the sum of the initial therapy cost, the cost of the first endoscopy, the expected cost of an initial AE, and the expected cost of the rescue therapy branch (which is triggered only if the initial therapy fails).\n$$E[C_i] = (C_i + C_{endo} + q_i C_{AE,i}) + (1 - p_i) \\times (C_D + C_{endo} + q_D C_{AE,D})$$\n\nFirst, let's calculate the expected cost of the rescue branch if it is triggered:\n$$E[\\text{Cost}_{\\text{rescue branch}}] = C_D + C_{endo} + q_D C_{AE,D} = \\$9,600 + \\$1,200 + (0.02 \\times \\$500) = \\$10,800 + \\$10 = \\$10,810$$\n\nNow, we analyze each initial therapy option.\n\n**1. Initial Therapy: Proton Pump Inhibitor (PPI)**\n- Given: $p_{PPI} = 0.42$, $C_{PPI} = \\$200$, $q_{PPI} = 0.01$, $C_{AE,PPI} = \\$300$.\n- **Remission Probability:**\n  $$R_{overall,PPI} = 0.42 + (1 - 0.42) \\times 0.75 = 0.42 + 0.435 = 0.855$$\n  Since $0.855 \\ge 0.85$, this strategy is valid.\n- **Expected Cost:**\n  $$E[C_{PPI}] = (\\$200 + \\$1,200 + 0.01 \\times \\$300) + (1 - 0.42) \\times \\$10,810$$\n  $$E[C_{PPI}] = \\$1,403 + 0.58 \\times \\$10,810 = \\$1,403 + \\$6,269.80 = \\$7,672.80$$\n\n**2. Initial Therapy: Swallowed Topical Corticosteroid (STC)**\n- Given: $p_{STC} = 0.65$, $C_{STC} = \\$650$, $q_{STC} = 0.03$, $C_{AE,STC} = \\$150$.\n- **Remission Probability:**\n  $$R_{overall,STC} = 0.65 + (1 - 0.65) \\times 0.75 = 0.65 + 0.2625 = 0.9125$$\n  Since $0.9125 \\ge 0.85$, this strategy is valid.\n- **Expected Cost:**\n  $$E[C_{STC}] = (\\$650 + \\$1,200 + 0.03 \\times \\$150) + (1 - 0.65) \\times \\$10,810$$\n  $$E[C_{STC}] = (\\$1,850 + \\$4.50) + 0.35 \\times \\$10,810 = \\$1,854.50 + \\$3,783.50 = \\$5,638.00$$\n\n**3. Initial Therapy: Six-Food Elimination Diet (SFED)**\n- Given: $p_{SFED} = 0.54$, $C_{SFED} = \\$400$, $q_{SFED} = 0$, $C_{AE,SFED} = \\$0$.\n- **Remission Probability:**\n  $$R_{overall,SFED} = 0.54 + (1 - 0.54) \\times 0.75 = 0.54 + 0.345 = 0.885$$\n  Since $0.885 \\ge 0.85$, this strategy is valid.\n- **Expected Cost:**\n  $$E[C_{SFED}] = (\\$400 + \\$1,200 + 0 \\times \\$0) + (1 - 0.54) \\times \\$10,810$$\n  $$E[C_{SFED}] = \\$1,600 + 0.46 \\times \\$10,810 = \\$1,600 + \\$4,972.60 = \\$6,572.60$$\n\n**Comparison and Conclusion:**\nWe compare the expected costs of the three valid strategies:\n- PPI Strategy: $E[C_{PPI}] = \\$7,672.80$\n- STC Strategy: $E[C_{STC}] = \\$5,638.00$\n- SFED Strategy: $E[C_{SFED}] = \\$6,572.60$\n\nThe minimal expected total cost among the valid strategies is $\\$5,638.00$, which corresponds to the STC strategy. The problem asks to round the answer to four significant figures. The value $5638$ already has four significant figures.\n\nThe minimal expected total cost is $5638$ USD.", "answer": "$$\n\\boxed{5638}\n$$", "id": "4832507"}]}